Clinical Trials - May 20, 2026
Oncopeptides secures regulatory approval to start Window-of-Opportunity study
Oncopeptides' clinical trial application for the "Window-of-Opportunity" (WoO) study in glioblastoma has been formally approved in Norway.
New Market - May 20, 2026
Lundbeck receives orphan drug designation in Japan
The orphan drug designation has been granted for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing’s disease.
CDMO - May 20, 2026
Diamyd Medical receives GMP certification and manufacturing authorization
The company has now received GMP (Good Manufacturing Practice) certification as well as manufacturing authorization from the Swedish Medical Products Agency for the production of biological investigational medicinal products for human use.
Collaboration - May 20, 2026
Herantis Pharma partners with Indivi
Herantis Pharma has announced a collaboration with Indivi, a Basel-based TechBio company focused on advancing precision medicine in neuroscience drug development, to integrate Indivi's digital biomarker platform into Herantis' upcoming Phase 2 proof-of-concept study of HER-096 in people living with Parkinson's disease.
Acquisition - May 19, 2026
LEO Pharma has acquired Replay
The acquisition adds expertise and a next generation gene therapy platform to LEO Pharma’s pipeline through Replay’s high‑payload herpes simplex virus (HSV) delivery vector.
Funding - May 19, 2026
MucoLife Therapeutics awarded funding from Medtech4Health and Vinnova
The company has been awarded funding through the program “Kompetensförstärkning i småföretag 2026.” The funding will support a new project focused on the development planning of a green, dual-use nebulization technology designed for delivery of MucoLife’s lead therapeutic candidate, MLT-001. MLT-001 is a first-in-class inhaled therapy being developed to rapidly dissolve pathological mucus plugs in […]
